Experts urge FDA to establish safety and access guidelines for psychedelic drugs; GSK to close German vaccine plant

Experts are urging the U.S. Food and Drug Administration to set clear safety and access standards for psychedelic medicines, according to the briefing.

The request reflects growing interest in therapeutic uses of psychedelics and a desire for defined regulatory pathways.

In a separate development, GSK said it will shut its vaccine manufacturing plant in Germany, citing low demand for its products.